Skip to content
DataLookout
Menu

SHINE-HFNCT05583773

SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved 1 year 7 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Aug 31, 2025 to Mar 31, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Study completion pushed from Dec 31, 2025 to Dec 31, 2027
    • Secondary endpoints: details revised at 5 of 9 entries
    • Site details revised at 8 of 26 sites
  2. Notable Eligibility criteria expanded, about 1 wordv12 Show 4 more changesShow less
    • Study sites: 21 to 26
    • Primary completion date: Apr 30, 2025 to Aug 31, 2025
    • Study title revised
    • Study description expanded, about 2 words
  3. Minor Study sites: 17 to 21v11
  4. Notable Enrollment target: 564 to 336v10
  5. Notable Eligibility criteria revised
    • Interventions: Placebo (Other), Shengxian Quyu Decoction (Drug) to Placebo (Other), ShengXian-QuYu Decoction (Drug)
    • Study description shortened, about 1 word
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Enrollment target: 308 to 564
    • Study sites: 4 to 17
    • Study title shortened, about 1 word
    v8
  2. Notable Primary endpoint revised
    • Study sites: 3 to 4
    • Secondary endpoints revised (9)
    v7
  3. Minor Study sites: 2 to 3v6
  4. Minor Study sites: 1 to 2v5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 7, 2023 to Mar 29, 2023
    v4
  6. Notable Start date: Dec 10, 2022 to Feb 7, 2023v3
  7. Notable Start date: Nov 1, 2022 to Dec 10, 2022v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change From Baseline in the KCCQ Clinical Summary Score
Timeframe: Up to 12 weeks

Secondary (8)

Change From Baseline in the Traditional Chinese Medicine Syndrome Score Scale (TCMSSS)
Change in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance
Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
Change in Left Ventricular Systolic Function
Change in Left Ventricular End-Diastolic Diameter
Show 3 moreShow less
Change in Left Ventricular End-Systolic Diameter
Change in Estimated Glomerular Filtration Rate from Baseline
Change From Baseline in the KCCQ Clinical Summary Score

Arms and interventions

ShengXian-QuYu DecoctionActive comparator

Patients will be randomized 1:1 to either ShengXian-QuYu Decoction or placebo. "ShengXian-QuYu Decoction" (calculated by a medicine): 30g of Astragalus membranaceus (Huangqi), 12g of Cornus officinalis (Shanzhuyu), 9g of Panax ginseng (Hongshen), 12g of Anemarrhena asphodeloides (Zhimu), 8g of Cimicifuga foetida (Shengma), 8g of Bupleurum chinense (Chaihu), 10g of Platycodon grandiflorum (Jiegeng), 10g of Sparganium stoloniferum (Sanleng), 9g of Curcuma phaeocaulis (Ezhu), 3g of Whitmania pigra (Shuizhi).

placeboPlacebo comparator

Placebo matching ShengXian-QuYu Decoction

Drugs: ShengXian-QuYu Decoction

Other: Placebo

Sites

26 sites in 1 country